Scientific misconduct findings; administrative actions: Glennon, Eileen,

[Federal Register: November 24, 1998 (Volume 63, Number 226)]

[Notices]

[Page 64966-64967]

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[DOCID:fr24no98-96]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

Ms. Eileen Glennon, Harvard Medical School and Brigham and Women's Hospital: Based on a report submitted to the Office of Research Integrity (ORI) by the Harvard Medical School (HMS) on June 30, 1998, as well as additional information obtained by ORI during its oversight review, ORI found that Ms. Glennon, former research technician, Endocrine-Hypertension Division, Brigham and Women's Hospital (BWH), engaged in scientific misconduct arising out of certain biomedical research supported by a grant from the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), and a grant from the National Center for Research Resources (NCRR), NIH.

Specifically, Ms. Glennon fabricated data to plot standard curves while conducting radioimmunoassays to determine angiotensin II concentrations. When the assays appeared not to be working, which occurred in approximately half of the assays over a one year period, she used numbers from previous standard curves and then used the fabricated standard curve to determine the concentration of angiotensin II, thus producing false experimental results. Ms. Glennon cooperated fully with the institutional inquiry panel and admitted her acts.

Ms. Glennon has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which she has voluntarily agreed, for the three (3) year period beginning November 13, 1998:

(1) To exclude herself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and

(2) That any institution that submits an application for PHS support for a research project on which her participation is proposed or which uses her in any capacity on PHS supported research, or that submits a report of PHS-funded research in which she is involved, must concurrently submit a plan for supervision of her duties to the

[[Page 64967]]

funding agency for approval. The supervisory plan must be designed to ensure the scientific integrity of Ms. Glennon's research contribution. The institution also must submit a copy of the supervisory plan to ORI.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443-5330. Chris B. Pascal, Acting Director, Office of Research Integrity.

[FR Doc. 98-31352Filed11-23-98; 8:45 am]

BILLING CODE 4160-17-P